Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ziopharm Ocology Inc (NASDAQ: ZIOP) has
Here's a roundup of top developments in the biotech space over the last 24 hours.
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollme...
During Friday's session, 445 companies made new 52-week lows.
Gainers
https://clinicaltrials.gov/ct2/show/NCT05124743
Raymond James maintains ZIOPHARM Oncology (NASDAQ:ZIOP) with a Market Perform and lowers the price target from $3 to $2.
